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Abstract
‘Masked hypertension’ is defined as having non-elevated clinic blood pressure (BP) with elevated
out-of-clinic average BP, typically determined by ambulatory BP monitoring. Approximately 15–
30% of adults with non-elevated clinic BP have masked hypertension. Masked hypertension is
associated with increased risks of cardiovascular morbidity and mortality compared to sustained
normotension (non-elevated clinic and ambulatory BP), which is similar to or approaching the risk
associated with sustained hypertension (elevated clinic and ambulatory BP). The confluence of
increased cardiovascular risk and a failure to be diagnosed by the conventional approach of clinic
BP measurement makes masked hypertension a significant public health concern. However, many
important questions remain. First, the definition of masked hypertension varies across studies.
Further, the best approach in the clinical setting to exclude masked hypertension also remains
unknown. It is unclear whether home BP monitoring is an adequate substitute for ambulatory BP
monitoring in identifying masked hypertension. Few studies have examined the mechanistic
pathways that may explain masked hypertension. Finally, scarce data are available on the best
approach to treating individuals with masked hypertension. Herein, we review the current
literature on masked hypertension including definition, prevalence, clinical implications, special
patient populations, correlates, issues related to diagnosis, treatment, and areas for future research.
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Traditionally, the diagnosis of hypertension is based on clinic blood pressure (BP), but the
use of ambulatory blood pressure monitoring (ABPM) along with clinic BP has made the
classification of hypertension more complex. The correlation between BP taken during
routine clinic visits and ambulatory BP is only moderate1. Thus, many individuals exhibit a
large discrepancy between these two measures. Figure 1 shows the four possible BP
categorizations derived from the combination of clinic and average ambulatory BP. For two
of the categories – sustained hypertension and sustained normotension – the classification is
concordant by the two methods of BP measurement. In the other two categories – white coat
hypertension and masked hypertension – the classification by the two methods is discordant.
Pickering et al2 first introduced the concept of white coat hypertension more than 25 years
ago, which is defined as having high clinic BP but normal ambulatory BP. White coat
hypertension occurs in 15–25% of people who are thought to be hypertensive by clinic
measurement3. The risk of cardiovascular disease (CVD) events in patients with white coat
hypertension is relatively low compared to patients with sustained hypertension, although
there has been some dispute about whether white coat hypertension is a benign
phenotype3,4.
In 2002, Dr. Pickering, Dr. Schwartz and colleagues coined the term ‘masked hypertension’
to describe the condition of non-elevated clinic BP with elevated average ambulatory BP5.
Unlike white coat hypertension, masked hypertension has consistently been shown to be
associated with a greater risk of CV target-organ damage, CVD, and mortality, compared
with sustained normotension. Although masked hypertension is increasingly being
recognized as an important clinical entity, many questions remain. Herein, we review the
current literature on masked hypertension including definition, prevalence, clinical
implications, issues with diagnosis, correlates, treatment, and areas for future research.
References for this review were identified through searches of PubMed as of July 2013,
using the key words “masked hypertension”, “isolated ambulatory hypertension”, “reverse
white coat hypertension” or “white coat normotension”. Searches were limited to
publications in English. We reviewed the articles identified from these searches (612
published papers) and relevant references cited in these articles. We focused our review on
masked hypertension in individuals not taking antihypertensive medications. However,
where appropriate, we do briefly discuss masked hypertension in individuals taking
antihypertensive medications.
DEFINITION
For the diagnosis of masked hypertension, non-elevated clinic BP is typically defined as
<140/90 mmHg6. However, the cutpoint for elevated out-of-clinic BP varies more than
clinic BP in the published literature. Studies differ on whether mean awake ambulatory BP
or mean 24-hour ambulatory BP is used to define masked hypertension4,7. The most widely
used definition, by our group and other investigators8,9, for elevated ambulatory BP has
been a mean awake ambulatory BP ≥135/85 mmHg. However, other definitions such as
mean 24-hour ambulatory BP ≥125/79 mmHg4 or ≥130/80 mmHg10 have been used.
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Nighttime (or sleep) BP has also been used as a criterion for masked hypertension given the
independent predictive value of nighttime BP for cardiovascular events11. The European
Society of Hypertension position paper12 incorporates elevated nighttime BP (≥120/70
mmHg) as part of the definition of masked hypertension: non-elevated clinic BP with
elevated mean awake ambulatory BP and/or elevated mean 24-hour ambulatory BP, and/or
elevated mean nighttime ambulatory BP. Individuals with non-elevated clinic BP and
elevated mean nighttime ambulatory BP have masked nocturnal hypertension12. Individuals
with non-elevated clinic BP and elevated mean nighttime ambulatory BP with normal mean
awake ambulatory BP have isolated (masked) nocturnal hypertension12.
The term masked hypertension was originally used to describe individuals not taking
antihypertensive medications5. However, many prevalence and outcome studies4,5,7,13 have
also included participants on antihypertensive medications, which effectively combines two
distinct masked hypertension populations (those not taking and those taking
antihypertensive medications). The term ‘masked uncontrolled hypertensives’ has been used
to describe treated individuals with non-elevated clinic but elevated ambulatory BP whereas
“masked hypertension” has been used to describe untreated individuals12,14. A recent
European Society of Hypertension position paper12 suggested that masked hypertension and
masked uncontrolled hypertension be separately defined entities.
PREVALENCE IN THE GENERAL POPULATION
Table 1 lists large (>500 participants) prospective cohort studies of masked hypertension in
individuals recruited from the general population. As Table 1 shows, the overall prevalence
in the general population ranges from 8.5 to 16.6%, and the prevalence ranges from 14.7 to
30.4% when restricted to participants with non-elevated clinic BP. The variability in
prevalence estimates is attributed to the heterogeneous definition of masked hypertension,
and differences in the sample characteristics and populations across studies.
In the U.S., population estimates of masked hypertension are scarce. In a study of adult
employees conducted in New York, we found that the prevalence of masked hypertension
among those with non-elevated clinic BP who were not taking antihypertensive medications
and had no history of overt CVD was 15.2%8.
CLINICAL IMPLICATIONS
Bjorklund et al15 demonstrated an increased risk of cardiovascular events with masked
hypertension in a study of 578 untreated 70-year old men in Sweden (Table 1). After a mean
5.9 years of follow up, compared to those with sustained normotension, the adjusted hazard
ratio for cardiovascular morbidity was 2.77 (95% CI 1.15 to 6.68) in the masked
hypertension group and 2.94 (95% CI 1.49 to 5.82) in the sustained hypertension group.
However, Hansen et al7 studied 1700 Danish men and women and demonstrated that
compared with sustained normotension, only sustained hypertension and not masked
hypertension had a statistically significant adjusted HR for cardiovascular mortality,
ischemic heart disease and stroke: HR for sustained hypertension was 2.10 (95% CI 1.45–
3.06) whereas the HR for masked hypertension was 1.52 (95% CI 0.91–2.54).
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Meta-analyses have provided more consistent findings. Fagard and Cornelissen published a
meta-analysis of seven studies involving 11,502 participants – recruited not only from the
general population (4 studies), but also from primary care clinics (2 studies) and specialty
clinics (one study) – on the occurrence of cardiovascular events in people with white coat
hypertension, masked hypertension, and sustained hypertension3. In two studies, home BP
monitoring (HBPM) was used instead of ABPM to define masked hypertension. Over a
mean follow up of 8 years, compared to sustained normotension, the adjusted hazard ratios
for CVD events were 1.12 (95% CI 0.84 to 1.50) for white coat hypertension, 2.00 (95% CI
1.58 to 2.52) for masked hypertension, and 2.28 (95% CI 1.87 to 2.78) for sustained
hypertension. The results did not differ significantly across the studies (P=0.89).
Investigators from Denmark, Belgium, Japan and Sweden created the International Database
of Ambulatory BP in Relation to Cardiovascular Outcomes or IDACO database using
eligible data from four population-based cohort studies including ULSAM (Uppsala
Longitudinal Study of Adult Men), Ohasama, MONICA 1 (Multinational Monitoring of
Trends and Determinants in Cardiovascular Disease), and the Belgian Population Study16.
Using individual-level data from this database, Hansen et al.16 examined differences in
cardiovascular risk in participants with white coat hypertension, masked hypertension, and
sustained hypertension in 7,030 participants. At a median follow up of 9.5 years (64,958
person years), compared to sustained normotension, the adjusted hazard ratios for
cardiovascular events were 1.22 (95% CI 0.96–1.53) for white coat hypertension, 1.62 (95%
CI 1.35–1.96) for masked hypertension, and 1.80 (95% CI 1.59–2.03) for sustained
hypertension. The hazard ratios between masked hypertension and sustained hypertension
were not significantly different (P=0.14).
Findings from most individual cohort studies, and results from two meta-analyses
demonstrate that individuals with masked hypertension carry an increased cardiovascular
risk compared to individuals with sustained normotension. The cardiovascular risk
associated with masked hypertension approaches the risk associated with sustained
hypertension.
MASKED HYPERTENSION IN SPECIAL PATIENT POPULATIONS
TREATED HYPERTENSION—The prevalence of masked hypertension may differ based
on whether individuals are taking antihypertensive medications. For example, in a study by
Franklin et al17 that examined 12,148 participants from the IDACO database, with masked
hypertension defined as clinic BP < 140/90 mmHg and daytime ambulatory BP ≥135/85
mmHg, among non-diabetic, clinic normotensives not on antihypertensive medications,
18.8% had masked hypertension. In contrast, among individuals taking antihypertensive
medications, 30.5% had masked uncontrolled hypertension. Masked uncontrolled
hypertension is also associated with an increased risk of mortality. A study by Ben-Dov et
al18 showed that among 2285 treated hypertensive patients, hazard ratios for all-cause
mortality were 1.88 (95% CI 1.08–3.27) for masked uncontrolled hypertension and 2.02
(95% CI 1.30–3.13) for sustained hypertension compared to white-coat uncontrolled
hypertension.
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DIABETES—Patients with diabetes have a higher prevalence of masked hypertension than
patients without diabetes17,19,20. Among 7,826 subjects from the IDACO database not
taking antihypertensive medications, the prevalence of masked hypertension (clinic BP <
140/90 mmHg and daytime ambulatory BP ≥135/85 mmHg) was higher in the clinic
normotensive participants with diabetes (29.3%) than without diabetes (18.8%)17. Over a
median follow up period of 11.0 years, in untreated diabetics, the adjusted risk for
cardiovascular events for masked hypertensives was higher than for sustained normotensives
(HR 1.96, 95% CI 0.97–3.97, P=0.059), and was similar to untreated stage 1 hypertensives
(HR 1.07, 95% CI 0.58–1.98, P=0.82) but less than stage 2 hypertensives (HR, 0.53, 95%
CI, 0.29–0.99; P=0.048)17.
CHRONIC KIDNEY DISEASE—Few studies have examined the prevalence of masked
hypertension in untreated individuals with chronic kidney disease (CKD). A study by
Gorostidi et al.21 showed that among 5,693 hypertensive individuals from the Spanish
ABPM Registry with CKD stages 1–5, the proportion of individuals with masked
hypertension, defined by clinic BP < 140/90 mm Hg and mean 24-hour ambulatory BP≥
130/80mm Hg, was 7.0% in all individuals, and 32.1% of patients with clinic normotension.
72.6% of the participants were on antihypertensive medications. Using data from a cross-
sectional study of 617 treated hypertensive African Americans with CKD from the African
American Study of Kidney Disease cohort study (AASK), Pogue et al.13 reported that the
prevalence of masked uncontrolled hypertension, defined as having controlled clinic BP
(<140/90 mm Hg) but elevated daytime (≥135/ 85 mm Hg) and/or elevated nighttime
(≥120/70 mm Hg) ambulatory BP was 70%among individuals with controlled clinic BP.
Elevated nighttime ambulatory BP with or without elevated daytime ambulatory BP was the
most common phenotype (94.3%) of masked hypertension. Masked uncontrolled
hypertension was associated with increased proteinuria and left ventricular hypertrophy
compared to those with controlled clinic BP or white-coat hypertension. It is unclear what
portion of the high prevalence of masked hypertension (70%) among individuals with
controlled clinic BP was explained by antihypertensive medication use and/or by the
presence of CKD.
OBSTRUCTIVE SLEEP APNEA—Baguet et al.22 examined 133 newly diagnosed
obstructive sleep apnea patients, free of known cardiovascular disease and taking no
medications, and found 39 patients (30.0%) exhibited masked hypertension defined as non-
elevated clinic BP and a mean 24-hour ambulatory BP ≥125/80 mm Hg. Interestingly, in 61
male clinic normotensive individuals free of known cardiovascular disease and taking no
medications, Drager et al.23 found that obstructive sleep apnea was also associated with
masked hypertension using mean awake ambulatory BP, suggesting that sleep apnea also
adversely affects ambulatory BP beyond the sleep period. In a randomized controlled trial of
36 patients with obstructive sleep apnea on no medications randomized to either continuous
positive airway pressure (CPAP) or no CPAP, Drager et al.24 found that CPAP reduced
clinic and ambulatory BPs, and the proportion of patients with masked hypertension fell
from 39% to 5% (P = 0.04) only in the CPAP group.
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OTHER CORRELATES OF MASKED HYPERTENSION
Masked hypertension shares many of the same correlates as clinic hypertension including
increasing age, male gender, obesity, chronic kidney disease and diabetes25,26. However,
these factors do not vary from the clinic to ambulatory settings, suggesting that there may be
additional factors associated with the out-of-clinic setting that are associated with a selective
increase in ambulatory BP over clinic BP.
PHYSICAL ACTIVITY
While patients are instructed to rest for several minutes prior to clinic BP measurements,
ABPM takes readings while the patient is active throughout the day. Exaggerated BP
responses to physical activity or exercise may increase the likelihood of masked
hypertension among patients with non-elevated clinic BP. Sharman et al examined the
prevalence of masked hypertension among 72 untreated participants with a hypertensive
response to exercise (defined as clinic BP <140/90 mmHg and exercise SBP ≥ 210 mmHg in
men or ≥ 190 mmHg in women, or DBP ≥ 105 mmHg)27. In this group, masked
hypertension was highly prevalent (42 of 72 participants, 58%) and was associated with
increased left ventricular mass index compared to participants with clinic normotension
without a hypertensive response to exercise. In a group of 85 sedentary patients with
diabetes and clinic normotension, Akilli et al demonstrated that masked hypertension was
associated with decreased exercise capacity and exaggerated BP response on exercise
treadmill testing25. In a case-control study of patients with diabetes, Kramer et al showed
that in 37 patients with sustained normotension and 24 patients with masked hypertension
who all underwent exercise treadmill testing, the proportion of patients who reached a
systolic peak value of > 180 mmHg was higher in patients with masked hypertension
(70.8%) than in those with sustained normotension (21.1%) and a peak SBP of >170 mmHg
had 70% sensitivity and 73% specificity for identifying patients with masked
hypertension28. It is possible that ABPM is detecting abnormally elevated BP in response to
physical activity in the naturalistic setting that is not detected with clinic BP alone.
MENTAL STRESS
In addition to physical stress, out-of-clinic BP measurements may also be influenced by
psychological stress. To determine if psychosocial stress at work affects the prevalence of
masked hypertension, Trudel et al obtained BP measurements from 2,357 workers (mean
age 44 years, 61% women)29. In men, having both high psychological demands and high
decision latitude was associated with an odds ratio of 2.07 (95% CI 1.30 − 3.31) for masked
hypertension compared to the passive group. Interestingly, among women, there was no
significant association between high psychological demands/high decision latitude and
masked hypertension. In a study looking at working conditions and masked hypertension by
Landsbergis et al., 45 men and 119 women hospital and home care employees/volunteers
were studied. Masked hypertension was observed in 24% of men and 17.6% of women with
non-elevated clinic BPs, and was associated with evening, night and rotating shiftwork
(odds ratio of 8.2, 95% CI 2.1 to 40.3). A combination of job strain and effort-reward
imbalance had an odds ratio of 3.0 (95% CI 1.0 to 8.6) for masked hypertension after
adjusting for age30. In a meta-analysis of 22 cross-sectional studies looking at job strain and
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ambulatory BP, Landsbergis et al.31 found that job strain was associated with a 3.4 mmHg
(95% CI 2.0 to 4.8) increase in work systolic BP. These studies demonstrate an association
between out-of-clinic job related stress and BP which may increase the likelihood of masked
hypertension.
SMOKING AND ALCOHOL
In the meta-analysis by Verberk et al.26, the investigators found that participants with
masked hypertension were more often smokers than were participants with either sustained
normotension, white coat hypertension or sustained hypertension. Ishikawa et al.32
demonstrated that among 405 treated hypertensive patients with well-controlled clinic BPs,
246 patients (60.7%) had masked hypertension in the morning by HBPM. Patients who self-
reported having at least one alcohol beverage every day, had an increased odds ratio (1.76,
95% CI 0.99 to 3.12, p=0.05) for morning-masked hypertension versus those who did not
drink every day.
These out-of-clinic correlates of masked hypertension support the hypothesis that
environmental factors are associated with BP in ways that are not detectable by clinic BP
alone. Further research is required to determine if these associations are causal.
BIOLOGIC CORRELATES
Arterial stiffness, inflammation and endothelial dysfunction are associated with masked
hypertension. Veerabhadrappa et al.33 studied endothelial function and inflammation in 50
African Americans with clinic prehypertension and found that the 58% of patients with
masked hypertension had impaired endothelial function and elevated levels of high
sensitivity C-reactive protein compared to patients with true prehypertension (i.e., without
elevated ambulatory BP). It is unclear whether these factors are selectively associated with
masked hypertension or are also associated with sustained hypertension. It is possible that
these biological correlates affect ambulatory BP first then clinic BP later, suggesting that
masked hypertension is a precursor of sustained hypertension, which is a natural history we
previously proposed8. Another possibility is that these biological factors interact with
clinical and environmental factors to elevate BP outside the clinic setting in patients with
masked hypertension. Because these associations are cross-sectional, causal direction cannot
be ascertained. It is certainly possible that masked hypertension induces inflammation and
endothelial function, rather than the other way around.
ISSUES RELATED TO PROPER DIAGNOSIS
In addition to the variation in the cutpoint used to define elevated ABP across studies,
another source of variability in the diagnosis of masked hypertension is the number of valid
ABPM readings required during either the awake or sleep period or 24-hour period4,7–9.
An additional issue is whether HBPM is an acceptable alternative to ABPM for measuring
out-of-clinic BPs. As noted above, the original definition of masked hypertension by
Pickering et al5 indicated ABPM for the out-of-clinic BP assessment; however, some studies
have used HBPM instead of ABPM34–37. Viera et al10 evaluated the congruence of the
diagnosis of masked hypertension comparing ambulatory and home BP monitoring in 50
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participants with normal or elevated clinic BP (110–159/70–99 mmHg). Among the entire
sample, ABPM and HBPM had only a 46.7% agreement in diagnosing masked hypertension
when paired with their corresponding clinic BP measurement. In the PAMELA study4,
home BP was elevated (defined as ≥135/83mmHg) in only half of the patients diagnosed
with masked hypertension by mean 24-hour ambulatory BP (defined as ≥125/79 mmHg),
again suggesting limited agreement between ambulatory and home BP readings in
diagnosing masked hypertension. Finally, given that some studies have incorporated sleep
BP in the definition of masked hypertension12,13, HBPM may not be an ideal methodology
for identifying masked hypertension due to the inability of most devices to measure BP
during sleep.
Despite the poor agreement between ABPM and HBPM in diagnosing masked hypertension,
the diagnosis of masked hypertension by ABPM versus HBPM may have similar prognostic
value. Angeli et al performed a meta-analysis on the risk of major cardiovascular disease in
participants with masked hypertension stratified by out-of-clinic BP measurements with
either ABPM or HBPM38. They found the hazard ratio of major cardiovascular disease to be
2.00 (95% CI 1.54 to 2.60, P < 0.001) for masked hypertension diagnosed by ABPM and
2.13 (95% CI 1.35 to 3.35, P = 0.001) for masked hypertension diagnosed by HBPM
suggesting the risk associated with masked hypertension may not be affected by how out-of-
clinic BP is measured. In the PAMELA study4, even though there was limited agreement
between home and ambulatory BP readings in diagnosing masked hypertension, left
ventricular mass index was similar between the participants who were diagnosed with
masked hypertension by either 24-hour ABPM or HBPM.
The poor agreement between ABPM and HBPM in diagnosing masked hypertension while
having similar relations with end-organ damage and cardiovascular outcomes is interesting.
It could imply that both forms of out-of-clinic BP measurements are identifying non-
overlapping populations of people with masked hypertension and similar cardiovascular
risk. Alternatively and probably less likely, it could reflect the inability of either
measurement modality to pick up all cases of masked hypertension with a single set of
measurements. As these studies did not examine the contribution of masked nocturnal
hypertension, which cannot be determined by HBPM, further research is needed to better
elucidate these issues.
An equally important, but perhaps underappreciated issue is how clinic BP is ascertained.
Myers et al compared conventional (manual) versus automated measurement of BP in 555
patients with systolic hypertension and no serious comorbidities in 67 primary care practices
and found that the average manual clinic BP (149.5/81.4mmHg) was significantly higher
than automated measurements (135.6/77.7 mmHg)39. These findings could reflect
attenuation of the white coat response with the automated device. When compared to 24-
hour ambulatory monitoring as a gold standard, the accuracy of automated clinic BP
measurements was significantly better than manual BP measurements. In a separate study,
Myers et al.40 demonstrated that the presence of masked hypertension was lower using
automated clinic BP measurements. Across three clinic visits, masked hypertension was
identified in a total of 42.1% single patient visits for automated clinic BP, and 60.7%single
patient visits for manual clinic BP. It is plausible that the lower prevalence of masked
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hypertension associated with automated clinic BP reflects the greater correlation of
ambulatory BP with automated versus manual clinic BP.
PRACTICAL APPROACH TO THE DIAGNOSIS OF MASKED
HYPERTENSION
There is limited evidence on the best approach for detecting masked hypertension in
individuals not taking antihypertensive medications. One approach would be to perform
ABPM on everyone with non-elevated clinic BP. In 2011, based on a cost-effectiveness
analysis, the National Institute for Health and Care Excellence (NICE) recommended that all
patients with elevated clinic BP have ABPM to exclude white coat hypertension41. No study
has been conducted on whether a parallel approach (i.e. performing ABPM in individuals
with clinic normotension) would also be cost effective.
Given the added cost of ABPM, another approach would be to target screening to
individuals whose risk for having masked hypertension exceeds some pre-specified
threshold. Our group has previously examined the diagnostic overlap between masked
hypertension and prehypertension (SBP 120–139mmHg or DBP 80–89mmHg)8. In a
worksite-based study of 813 participants not on antihypertensive medications and free of
cardiovascular disease, 769 participants had non-elevated clinic BP. The overall prevalence
of masked hypertension in the participants with non-elevated clinic BP was 15.2% using a
cutoff of 135/85 mmHg for mean awake ambulatory BP. In the subgroup of participants
with prehypertension, the prevalence of masked hypertension increased to 34% and reached
52% in the higher prehypertensive range (SBP 130–139 mmHg or DBP 80–89 mmHg),
whereas the prevalence of masked hypertension was only 3.9% in participants with normal
clinic BP (SBP < 120 mmHg and DBP < 80 mmHg). Other studies have similarly shown
that clinic BPs in the upper prehypertensive range predict masked hypertension42.
Therefore, a diagnostic approach may be to test individuals for masked hypertension if their
clinic BP is in the prehypertensive range (Figure 2). If clinic BP is <120/80 mmHg there
may be no need to do ABPM since the prevalence of masked hypertension in this group is
low. An additional approach would be to perform targeted testing among untreated
individuals who have a high prevalence of masked hypertension, including those with
diabetes, obstructive sleep apnea, and possibly CKD.
Important questions remain including whether non-research clinic BPs obtained in routine
practice can be used, whether this approach is valid across a broad range of age, gender, and
racial/ethnic groups, and whether HBPM is useful as an intermediary assessment tool for
deciding on whom to perform ABPM.
TREATMENT
One approach to the treatment of masked hypertension would be to reduce ambulatory BP in
masked hypertensives, using antihypertensive medications, despite the absence of elevated
clinic BP and then perform periodic ABPM to determine on-treatment ambulatory BP.
While it is assumed that lowering ambulatory BP will have similar clinical benefits to
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lowering clinic BP43, it is still unclear if the treatment of masked hypertension is associated
with a reduction in clinical adverse events. In a randomized, double-blind, placebo-
controlled study, Hare et al44 examined the impact of fixed dose spironolactone (25mg
daily) in 115 untreated participants without a history of hypertension, but with a
hypertensive response to exercise (exercise SBP ≥ 210 mmHg in men or ≥ 190 mmHg in
women, or DBP ≥ 105 mmHg). In a subgroup analysis of the 40% of participants with
masked hypertension based on daytime ABPM using a cutoff of 135/85 mmHg, the
spironolactone group showed significantly greater reductions in exercise systolic BP
(−10.0±12.9 mmHg vs. 0.3±8.7 mmHg, P < 0.01) and 24-hour ambulatory pulse pressure
(−2.4 ± 4.7 mmHg vs. 2.1 ± 8.4 mmHg, P < 0.05); effects on 24-hour systolic and diastolic
ambulatory BP were not reported. However, no difference in left ventricular mass index
reduction was observed between the spironolactone and placebo groups after three months.
Another treatment paradigm is to consider masked hypertension a prognostic marker of
increased CVD and mortality, and rather than treating ambulatory BP, the focus would be on
aggressively treating the modifiable risk factors associated with masked hypertension
including obesity, diabetes, sleep apnea, and avoidance of smoking and alcohol intake.
Masked hypertension may identify a “high risk” group that requires aggressive CVD risk
factor control.
Given that there is some evidence that masked hypertension predicts subsequent sustained
hypertension45, a third paradigm is to wait for individuals with masked hypertension to
manifest sustained hypertension. This approach would include performing clinic BP
measurements and ABPM at frequent intervals to diagnose sustained hypertension or
exclude other phenotypes such as sustained normotension, and less commonly white coat
hypertension, which may also follow an initial diagnosis of masked hypertension45.
FUTURE RESEARCH
Many important questions regarding masked hypertension remain unanswered. Table 2
summarizes relevant questions. In order to further unmask the extent of masked
hypertension’s public health impact and establish effective clinical screening and treatment
guidelines, these questions should be addressed through focused research.
CONCLUSIONS
Masked hypertension is associated with an increased risk of cardiovascular morbidity and
mortality compared to sustained normotension. If we assume that the prevalence of masked
hypertension ranges from 15 to 30%in the U.S. adult population of approximately 160
million with non-elevated clinic BP, then currently it is estimated that 24 to 48 million
American adults may be at increased risk for heart disease and stroke due to masked
hypertension. There are fundamental issues about masked hypertension that need to be
addressed. These include standardizing the definition for diagnosis, comparing the cost-
effectiveness of strategies for screening and detection, gaining further insight into the
mechanisms that underlie masked hypertension, and determining the optimal treatment
strategy for treating masked hypertension. Until these issues are addressed, masked
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hypertension will likely remain outside mainstream clinical care, and this public health
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Four hypertension categories based on clinic and ambulatory BP measurements. In sustained
hypertension and sustained normotension, clinic BP and ambulatory BP categories agree.
Sustained normotension is defined as non-elevated clinic and ambulatory BP. Sustained
hypertension is defined as elevated clinic and ambulatory BP. White coat hypertension is
defined as elevated clinic BP with normal ambulatory BP. Masked hypertension is defined
as non-elevated clinic BP with elevated ambulatory BP. Elevated clinic BP is typically
defined as ≥140/90 mmHg. Elevated ambulatory BP is typically defined as mean awake
ambulatory BP ≥135/85 mmHg, although other cutpoints have been proposed (see review).
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A possible diagnostic approach for the identification of masked hypertension in the general
population. BP: blood pressure
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Table 2
Important questions that remain unanswered in the area of masked hypertension
What ambulatory blood pressure cutpoint should be used in the definition of masked hypertension?
How many clinic (and over how many visits) and ambulatory readings should be obtained for the diagnosis of masked hypertension?
Which ambulatory blood pressure monitoring time frame (daytime, nighttime, or 24 hours) should be used in the definition of masked
hypertension?
Should manual or automated devices be used for clinic blood pressure assessment for the diagnosis of masked hypertension?
What diagnostic strategy is most accurate and cost-effective for the detection of masked hypertension?
Should home blood pressure monitoring be used to diagnose masked hypertension?
Does treatment of masked hypertension improve clinical outcomes?
Do patients with masked (uncontrolled) hypertension taking antihypertensive medications have the same prognosis as patients with masked
hypertension on no antihypertensive medications?
Does treatment of these groups have similar benefits in reducing end-organ damage and adverse clinical outcomes?
What are the mechanisms that underlie masked hypertension?
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